Business
Ascletis Announces Ultra-Long-Acting Subcutaneous Depot Maintenance Formulation of Small Molecule GLP-1R Agonist ASC30 Demonstrated an Observed Half-Life of 75 Days in Participants with Obesity
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that ultra-long-acting subcutaneous (SQ) depot maintenance formulation of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 demonstrated an observed half-life of 75 days in participants with obesity (body mass index (BMI) ≥ 30 kg/m2) in a U.S. Phase Ib clinical study (NCT06679959), supporting once-quarterly administration as a maintenance therapy for chronic weight management. The ASC30 maintenance formulation was developed utilizi
About this update from Ascletis Pharma, Inc.
[{"type":"text","content":"- Maintenance formulation of small molecule ASC30 demonstrated an observed half-life of 75 days in participants with obesity in the U.S. Phase Ib study.","length":206,"tagName":"p"},{"type":"text","content":"- 75-day observed half-life supports once-quarterly administration. ","length":121,"tagName":"p"},{"type":"text","content":"- Once-quarterly SQ administration of ASC30 is the most clinically advanced once-quarterly incretin drug and has the potential to address a highly unmet need as a maintenance therapy for chronic weight management, representing a significant patient population.","length":319,"tagName":"p"},{"type":"text","content":"HONG KONG, Sept. 9, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that ultra-long-acting subcutaneous (SQ) depot maintenance formulation of small molecule GLP-1 receptor (GLP-1R) agonist ASC30 demonstrated an observed half-life of 75 days in participants with obesity (body mass index (BMI) ≥ 30 kg/m2) in a U.S. Phase Ib clinical study (NCT06679959), supporting once-quarterly administration as a maintenance therapy for chronic weight management. The ASC30 maintenance formulation was developed utilizing Ascletis' Ultra-Long-Acting Platform (ULAP).","length":637,"tagName":"p"},{"type":"text","content":"After a single SQ injection of ASC30 (100 mg) maintenance formulation in eight participants with obesity, the median time for ASC30 to reach maximum concentrations (Cmax) was 17 days post-dose. The time for ASC30 concentrations to reduce to fifty percent (50%) of ASC30's Cmax was approximately 75 days post-dose, demonstrating an observed half-life of 75 days.","length":365,"tagName":"p"},{"type":"text","content":""Maintenance therapy represents a significant unmet medical need for chronic weight management," said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. "For example, after a period of treatment with once-weekly administered incretin drugs that help reach weight loss goals, patients prefer to switch to a once-quarterly therapy to maintain the weight. Based on its promising pharmacokinetic&nbs...